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Background
In patients with ischemic stroke, endovascular treatment results in a higher rate of 
recanalization of the affected cerebral artery than systemic intravenous thrombo-
lytic therapy. However, comparison of the clinical efficacy of the two approaches is 
needed.
Methods
We randomly assigned 362 patients with acute ischemic stroke, within 4.5 hours 
after onset, to endovascular therapy (intraarterial thrombolysis with recombinant 
tissue plasminogen activator [t-PA], mechanical clot disruption or retrieval, or a 
combination of these approaches) or intravenous t-PA. Treatments were to be given 
as soon as possible after randomization. The primary outcome was survival free of 
disability (defined as a modified Rankin score of 0 or 1 on a scale of 0 to 6, with 
0 indicating no symptoms, 1 no clinically significant disability despite symptoms, 
and 6 death) at 3 months.
Results
A total of 181 patients were assigned to receive endovascular therapy, and 181 in-
travenous t-PA. The median time from stroke onset to the start of treatment was 
3.75 hours for endovascular therapy and 2.75 hours for intravenous t-PA (P<0.001). 
At 3 months, 55 patients in the endovascular-therapy group (30.4%) and 63 in the 
intravenous t-PA group (34.8%) were alive without disability (odds ratio adjusted for 
age, sex, stroke severity, and atrial fibrillation status at baseline, 0.71; 95% confi-
dence interval, 0.44 to 1.14; P = 0.16). Fatal or nonfatal symptomatic intracranial 
hemorrhage within 7 days occurred in 6% of the patients in each group, and there 
were no significant differences between groups in the rates of other serious adverse 
events or the case fatality rate.
Conclusions
The results of this trial in patients with acute ischemic stroke indicate that endo-
vascular therapy is not superior to standard treatment with intravenous t-PA. (Fund-
ed by the Italian Medicines Agency, ClinicalTrials.gov number, NCT00640367.)
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Intravenous recombinant tissue plas-minogen activator (t-PA) is the standard treat-ment for acute ischemic stroke, but more 
than half the treated patients do not recover 
completely or die.1 Alternative treatments, such 
as endovascular treatment, have been used for 
many years. As compared with endovascular treat-
ment, intravenous thrombolysis is associated with 
a lower probability of recanalization2-9 (46% of 
cases with intravenous t-PA vs. >80% with endo-
vascular treatment10-15). Nevertheless, the two 
approaches have not been directly compared, re-
canalization is not invariably associated with a 
favorable clinical outcome,16 and it is not known 
whether clinical outcomes are superior with en-
dovascular therapy as compared with intrave-
nous t-PA.
Although previous randomized, controlled clin-
ical trials of endovascular treatment yielded prom-
ising results,8,15,17 the generalizability of these 
results remains questionable, because the trials 
involved highly selected patients, did not compare 
endovascular treatment with intravenous t-PA, and 
did not assess endovascular treatment as a mul-
timodal procedure. Many case series and obser-
vational cohort studies of endovascular treatment 
have shown encouraging clinical results, but there 
have been concerns about selection and publica-
tion biases.18
To investigate whether endovascular treatment, 
including the options of a mechanical device and 
intraarterial t-PA, is more effective than the cur-
rently available treatment with intravenous t-PA, 
we randomly assigned a total of 362 patients to 
the two treatment options, after a pilot study 
showed that prompt initiation of endovascular 
treatment is a safe and feasible alternative to 
intravenous t-PA.19
Me thods
Study Design
This was a pragmatic, multicenter, open-treatment 
clinical trial with a blinded end point20 (see Fig. 
S1 in the Supplementary Appendix, available with 
the full text of this article at NEJM.org), designed 
to test whether outcomes were better with endo-
vascular treatment than with intravenous t-PA. The 
study protocol was approved by the institutional 
review board at each participating center and is 
available at NEJM.org. The authors vouch for the 
completeness and accuracy of the data and data 
analysis and for the fidelity of this report to the 
study protocol. The study was funded by the Italian 
Medicines Agency (AIFA). The AIFA reimbursed 
participating hospitals for the catheters and de-
vices used in the trial and purchased t-PA from 
Boehringer Ingelheim Italia for use in the endo-
vascular-treatment group. There was no industry 
support for or industry involvement in this trial.
Inclusion and Exclusion Criteria
Patients with acute stroke and an age of 18 to 80 
years, in whom intracranial hemorrhage had been 
ruled out, were eligible if there was a clearly de-
fined time of stroke onset that allowed for im-
mediate initiation of intravenous t-PA therapy 
(defined as within 4.5 hours after symptom onset) 
or for the administration of endovascular treat-
ment as soon as possible (within 6 hours after 
symptom onset). Inclusion and exclusion criteria 
are listed in detail in the protocol.20 Competent 
patients gave written informed consent before 
enrollment; otherwise, a witnessed waiver of con-
sent was possible.21
Randomization
The study protocol provided for centralized, sim-
ple randomization online. A single randomization 
list was prepared with the use of a hardware sys-
tem, available at www.random.org. All patients 
underwent randomization within 4.5 hours after 
symptom onset.
Endovascular Treatment
Patients who were assigned to this treatment group 
did not receive intravenous t-PA while awaiting 
endovascular treatment. Angiography was tar-
geted to acquire data essential for guiding endo-
vascular therapy. Anticoagulant therapy was rec-
ommended with an initial bolus dose of 5000 IU 
of intravenous heparin, followed by an infusion 
of 500 IU per hour until the conclusion of the 
angiography. Once the diagnostic information 
had been acquired, the interventionist could con-
sider pharmacologic or mechanical thrombolysis 
or both. For pharmacologic thrombosis, a micro-
catheter was to be positioned close to (or within 
or beyond) the thrombus with the use of a micro-
guide; the full t-PA dose infused did not exceed 
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0.9 mg per kilogram of body weight (maximum, 
90 mg for patients with a body weight of ≥100 kg) 
and was to be delivered within 1 hour. If com-
plete recanalization was achieved before the max-
imum dose was reached, the t-PA infusion was 
stopped. The option of mechanical thrombolysis 
was left to each interventionist’s discretion. Me-
chanical thrombosis could involve the use of a 
micro-guidewire to facilitate disintegration of 
the thrombus, systems to capture and extract the 
thrombus, or more complex systems to crush and 
aspirate it.
In patients with a neurologic deficit but no 
corresponding occlusion, the endovascular pro-
cedure involved injecting t-PA into the vascular 
area that was presumably affected. The amount 
of drug to be injected, which again did not ex-
ceed 0.9 mg per kilogram (maximum, 90 mg for 
patients weighing ≥100 kg), was at the operator’s 
discretion. If the patient had no neurologic defi-
cit, t-PA was not given. The choice of general an-
esthesia or sedation to carry out a procedure was 
discretionary.
Intravenous Thrombolysis
Systemic thrombolytic treatment was to be started 
immediately after randomization, within 4.5 hours 
after symptom onset. Intravenous t-PA was admin-
istered at a dose of 0.9 mg per kilogram (maxi-
mum, 90 mg), with 10% given as an initial bolus 
and the remaining 90% as a constant infusion 
over a period of 60 minutes.
Associated Therapies
All patients in both treatment groups were given 
the most appropriate therapy related to the treat-
ments that they were assigned to receive. Anti-
platelet and anticoagulant agents were to be 
avoided during the first 24 hours after symptom 
onset, with the exception of heparin used during 
endovascular treatment and antiplatelet therapy if 
a stent was to be deployed during the procedure.
Assessment of Patients
Neurologic deficit was quantified with the use of 
the National Institutes of Health Stroke Scale 
(NIHSS), a 15-item scale that rates the level of 
neurologic impairment.22 Total NIHSS scores 
range from 0 to 42, with higher scores indicating 
more severe cerebral infarctions (scores of ≤6 in-
dicate mild neurologic impairment, and scores of 
≥25 indicate very severe impairment). Examiners 
were trained and certified in the use of the NIHSS. 
Patients were assessed with the scale at baseline 
and on day 7 or at discharge or transfer to an-
other hospital, whichever occurred first.
Long-term clinical condition was assessed 
90 days after randomization by means of a tele-
phone interview by a single neurologist, who was 
not aware of treatment assignments and who 
had specific training in outcome assessment 
with the modified Rankin Scale (which ranges 
from 0 to 6, with 0 indicating no symptoms and 
6 indicating death); the examiner used a check-
list of daily activities as a guide in questioning 
the patient.23,24 If a patient was not available, a 
proxy was interviewed.
Outcomes and Safety Measures
The primary outcome was disability-free survival 
at 90 days, with freedom from disability defined 
as a modified Rankin score of 0 (no symptoms) 
or 1 (no clinically significant disability despite 
symptoms). Secondary outcomes included the pro-
portion of patients with a mild neurologic deficit 
or none (NIHSS score, ≤6) and the following 
safety measures, assessed at day 7 after throm-
bolysis: fatal and nonfatal symptomatic intracra-
nial hemorrhage, fatal and nonfatal symptomatic 
edema from an original brain infarction, fatal 
and nonfatal recurrent ischemic stroke, death from 
any cause, neurologic deterioration (defined as a 
increase of ≥4 points in the NIHSS score), and 
fatal and nonfatal extracerebral events. Evalua-
tions of secondary end points were performed by 
local neurologists, who were aware of treatment 
assignments.
Statistical Analysis
The estimation of the sample size for the pri-
mary outcome was based on a standard test of 
two samples per difference in binomial propor-
tions (two-tailed test) with an alpha level of 5% 
and a power of 80%. The study was designed to 
verify or refute an absolute difference of 15 per-
centage points between the proportions of pa-
tients with a favorable outcome in the two treat-
ment groups. The rationale for this effect size 
was based on the results of the pilot phase of the 
trial,19 which showed a nonsignificant absolute 
difference of 20 percentage points in favor of en-
dovascular treatment over intravenous t-PA; the 
favorable data on recanalization rates with endo-
vascular treatment (a difference of 17 to 37 per-
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centage points in indirect comparisons with intra-
venous t-PA10); and the need for a clinical effect 
sufficiently large to justify the switching from a 
well-established and simple procedure to one 
that is newer, more expensive, and more difficult 
to perform. We calculated that we would need to 
enroll at least 172 patients per study group, as-
suming that 40% of those treated with intrave-
nous t-PA would have a favorable outcome.
Intention-to-treat analyses were used through-
out the study. All analyses were performed by a 
statistician who was not aware of treatment as-
signments. The primary analysis compared the 
effects of endovascular treatment and intravenous 
t-PA on survival without disability (modified 
Rankin score of 0 or 1) at 90 days after enroll-
ment; for this purpose, the modified Rankin 
scores were dichotomized as 0 or 1 versus 2 to 
6 (including death). The binary score was then 
cross-tabulated against the type of treatment, 
and the results were evaluated with the use of a 
two-tailed Fisher’s exact test.
From the same tabulation, the Mantel–Haenszel 
odds ratio and its 95% confidence interval were 
obtained. A multivariate logistic-regression model 
was also used, with the binary end points as 
dependent variables, and including as indepen-
dent regressors the type of treatment and some 
possible confounders together with other vari-
ables having possible clinical relevance (age, sex, 
severity of neurologic deficit, and status with 
respect to atrial fibrillation). The 90-day relative 
survivorship (the proportion of observed to ex-
pected number of survivors) was also included in 
the analysis, assessed with the use of the Kaplan–
Meier product-limit method, followed by the log-
rank test.
Secondary analyses were performed on safety 
measures, again with the use of Fisher’s exact test. 
Subgroup analysis was then planned according 
to the main prognostic variables. All analyses 
were performed with the use of the Stata/SE 12.1 
statistical package (StataCorp); a P value of less 
than 0.05 was considered to indicate statistical 
significance.
R esult s
Characteristics of the Patients
Recruitment started on February 1, 2008, and 
ended on April 16, 2012. During this period, 362 
patients with acute ischemic stroke underwent 
randomization (181 to endovascular treatment and 
181 to intravenous t-PA). No patients were lost to 
follow-up, and no patients dropped out of the 
study (Fig. S1 in the Supplementary Appendix).
The two groups were generally well matched 
with regard to baseline characteristics (Table 1), 
except for atrial fibrillation, which was less fre-
quent in the endovascular-therapy group than in 
the intravenous t-PA group (in 8% of patients vs. 
16%, P = 0.02), and a diagnosis of dissection as 
the cause of the stroke, which was more fre-
quent in the endovascular-therapy group (8% vs. 
2%, P = 0.03).
Treatment Method
Of the 181 patients assigned to endovascular treat-
ment, 15 did not receive the treatment (6 because 
of clinical improvement, 3 because of a lack of evi-
dence of occlusion, 3 because of dissection, 1 be-
cause of an unknown bleeding diathesis, 1 because 
of a groin hematoma, and 1 because of the de-
layed availability of the interventionist). Three 
procedures had to be interrupted, owing to 
equipment breakdown (in one procedure) and in-
traprocedural complications (in two procedures). 
Endovascular treatment was thus completed in 
163 patients.
Among the 165 patients who received endo-
vascular treatment without an equipment break-
down requiring interruption, locoregional infusion 
of t-PA and fragmentation of the thrombus with 
a micro-guidewire were achieved in 109 patients, 
and in 56 patients, a device was added. The me-
dian t-PA dose was 40 mg (interquartile range, 
20 to 50). The most widely used devices were 
Solitaire (EV3/Covidien; in 18 patients), Penum-
bra (Penumbra; in 9 patients), Trevo (Concentric/
Stryker; in 5 patients), and Merci (Concentric/
Stryker; in 5 patients). During the procedure, 
intravenous heparin was infused in 57 patients, 
and 22 patients underwent general anesthesia.
In patients assigned to intravenous t-PA, the 
median dose of t-PA was 66 mg (interquartile 
range, 59 to 72). Three patients did not receive 
the treatment (one because of spontaneous im-
provement and two because they underwent 
thrombectomy).
Efficacy
The primary outcome at 90 days is shown in Fig-
ure 1. A total of 55 of the 181 patients (30.4%) in 
the endovascular-treatment group survived with-
The New England Journal of Medicine 
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out disability (modified Rankin score, 0 or 1), as 
compared with 63 of the 181 patients (34.8%) in 
the intravenous t-PA group (absolute difference, 
−4.4 percentage points; 95% confidence interval 
[CI], −14.1 to 5.2; crude odds ratio, 0.82; 95% CI, 
0.53 to 1.27; P = 0.37). The odds ratio adjusted for 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Endovascular Treatment 
(N = 181)
Intravenous t-PA  
(N = 181)
Age — yr 66±11 67±11
Male sex — no. (%) 106 (59) 103 (57)
Weight — kg 75±14 75±13
Blood pressure — mm Hg
Systolic 155±26 150±23
Diastolic 84±12 83±12
NIHSS score†
Median (interquartile range) 13 (9–17) 13 (9–18)
Range 2–26 3–24
Atrial fibrillation — no. (%) 14 (8)‡ 29 (16)‡
Antihypertensive therapy — no. (%) 102 (56) 105 (58)
Antidiabetic therapy — no. (%) 20 (11) 19 (10)
Antiplatelet therapy — no. (%) 73 (40) 59 (33)
Stroke cause on day 7 — no. (%)
Cardiogenic embolism 58 (32) 62 (34)
Dissection 14 (8)§ 4 (2)§
Large­artery atherosclerosis 55 (30) 50 (28)
Small­vessel disease 13 (7) 12 (7)
Other or unknown 39 (22) 53 (29)
Condition mimicking stroke 2 (1)¶ 0
Stroke territory on day 7 — no. (%)
Anterior circulation 160 (88) 170 (94)
Posterior circulation 18 (10) 11 (6)
Anterior and posterior circulation 1 (1) 0
Time from stroke onset to randomization — hr:min
Median (interquartile range) 2:28 (2:04–3:10) 2:25 (1:59–2:59)
Range 0:45–4:30 0:30–4:17
Time from stroke onset to start of treatment — hr:min‖
Median (interquartile range) 3:45 (3:14–4:20)** 2:45 (2:20–3:20)**
Range 1:30–5:55 0:55–4:30
*  Plus–minus values are means ±SD. There were no significant differences between groups unless otherwise indicated. 
The abbreviation t­PA denotes tissue plasminogen activator.
†  Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating 
more severe neurologic impairment.
‡ P = 0.02.
§  P = 0.03. The higher frequency of dissections in the endovascular­treatment group was probably due to the use of an­
giography as a diagnostic supplement.
¶ Conditions mimicking stroke were seizure in one patient and somatoform disorder in one patient.
‖  The time from stroke onset to the start of treatment in the endovascular­treatment group was calculated to the begin­
ning of intraarterial pharmacologic or mechanical thrombolysis. Patients who did not receive the assigned treatment 
(endovascular treatment or intravenous t­PA) were not included.
** P<0.001.
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the key variables (age, sex, initial stroke severity as 
measured by the NIHSS, and presence or absence 
of atrial fibrillation at baseline) was 0.71 (95% CI, 
0.44 to 1.14; P = 0.16). At 90 days, 26 patients in the 
endovascular-treatment group (14.4%) and 18 in 
the intravenous t-PA group (9.9%) had died (P = 0.22 
by the log-rank test). There were no significant dif-
ferences between the groups with respect to the 
secondary outcome measures (Table 2).
Safety
Complications in the 7 days after randomization 
in the endovascular-treatment group and the in-
travenous t-PA group included death, neurologic 
deterioration, fatal and nonfatal symptomatic in-
tracranial hemorrhage, fatal and nonfatal symp-
tomatic edema from an original brain infarction, 
nonfatal recurrent ischemic stroke, and extracere-
bral events. The incidence of events on day 7 was 
similar in the two groups, and none of the differ-
ences were significant (Table 2).
Subgroup Analysis
We performed subgroup analyses to assess the 
effect of treatment on the primary outcome in 
subcategories, with adjustment for the main 
prognostic variables and taking into account that, 
for any specific prognostic factor, the distribu-
tion of other factors might differ between sub-
categories. Overall, there was little difference in 
the adjusted effects of treatment in the sub-
groups (Fig. 2).
Major Protocol Deviations and Sensitivity 
Analyses
One center was withdrawn from the study after it 
had enrolled 12 patients for failure to comply 
with the treatment assignments, because 5 pa-
tients in the intravenous t-PA group had been 
treated with intravenous t-PA followed by endo-
vascular treatment (3 patients) or directly with 
endovascular therapy (2 patients), and 1 patient 
in the endovascular-treatment group had been 
given intravenous t-PA. To determine whether 
data from this center could have biased the final 
result, we did a post hoc sensitivity analysis on 
the primary outcome, excluding these 12 pa-
tients, all of whom had a poor outcome (modi-
fied Rankin score, 2 to 6), and found that the 
overall result was not affected (adjusted odds ra-
tio, 0.71; 95% CI, 0.43 to 1.14; P = 0.16).
There were eight other patients (five assigned 
to endovascular treatment) with major protocol 
deviations at six centers. We ran a sensitivity 
analysis that excluded these patients, and the 
results, again, were not qualitatively different 
(adjusted odds ratio, 0.70; 95% CI, 0.43 to 1.14; 
P = 0.15).
Discussion
This trial, which was powered to detect an ad-
vantage of 15 percentage points with endovascu-
lar treatment for the primary outcome, failed to 
show the superiority of endovascular therapy as 
compared with intravenous t-PA. The disability-
free survival rate was 4.4 percentage points lower 
after endovascular treatment than after intrave-
nous t-PA, with a 95% confidence interval rang-
ing from 14.1 percentage points lower to 5.2 per-
centage points higher.
The results for the secondary outcomes and 
the subgroup and sensitivity analyses were con-
sistent with the result for the primary outcome. 
The subgroup analysis suggested that the lack of 
superiority of endovascular treatment did not 
depend on the time to endovascular treatment, 
the stroke subtype, or the type of center. How-
ever, a larger sample might have permitted bet-
ter discrimination between effects in the sub-
groups of patients.
28
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Figure 1. Modified Rankin Score at 3 Months According to Treatment Group.
The primary outcome was disability­free survival at 3 months, with freedom 
from disability defined as a score of 0 or 1 on the modified Rankin scale 
(range, 0 to 6, with 0 indicating no symptoms, 1 no clinically significant dis­
ability despite symptoms, and 6 death). The number in each cell denotes the 
number of patients with that score. The statistical analysis plan specified di­
chotomized scores of 0 or 1 (good outcome) versus 2 to 6 (poor outcome). 
The proportion of patients with a modified Rankin score of 0 or 1 at 3 months 
was 30.4% with endovascular treatment and 34.8% with intravenous tissue 
plasminogen activator (t­PA). In the analysis adjusted for age, sex, stroke 
severity, and presence or absence of atrial fibrillation at baseline, the odds 
ratio with endovascular treatment was 0.71 (95% confidence interval, 0.44 to 
1.14; P = 0.16).
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Table 2. Secondary Outcomes at Day 7.*
Outcome
Endovascular Treatment
(N = 181)
Intravenous t-PA 
(N = 181) P Value
NIHSS score ≤6 — no. of patients (%)† 97 (54) 100 (55) 0.89
Neurologic deterioration — no. of patients (%)‡ 16 (9) 12 (7) 0.39
Death — no. of patients (%) 14 (8) 11 (6) 0.53
Symptomatic intracranial hemorrhage — no. of patients (%) 10 (6) 10 (6) 0.99
Nonfatal 6 9
Fatal 4 1
Symptomatic edema from original brain infarction —  
no. of patients (%)
37 (20) 32 (18) 0.53
Nonfatal 30 23
Fatal 7 9
Recurrent ischemic stroke — no. of patients (%) 4 (2) 4 (2) 0.99
Nonfatal 4 4
Fatal 0 0
Noncerebral event
Nonfatal or fatal — no. of patients (%) 10 (6) 5 (3) 0.29
Nonfatal — no. of patients (%) 7 4
Fatal — no. of patients (%) 3 1
Type of event — no. of events§
Severe extracranial bleeding 2¶ 2
Pulmonary embolism 1 0
Myocardial Infarction 4 2
Sepsis 1 0
Deep venous thrombosis 1 0
Pulmonary edema 2 2
* All outcomes were assessed on day 7±2.
† An NIHSS score of 6 or less indicates mild neurologic impairment.
‡ Neurologic deterioration was defined as an increase of 4 or more points in the NIHSS score.
§ Types of nonfatal events are not exclusive because a given patient could have more than one type.
¶ Both patients had a nonfatal hematoma at the point of angiographic access that required evacuation and blood replacement.
Figure 2 (facing page). Effect of Treatment on the Primary Outcome in Subgroups.
The odds ratio in each subgroup was adjusted for the effects of the key variables (age, sex, initial stroke severity, 
and presence or absence of atrial fibrillation at baseline). Initial stroke severity was measured by means of the Na­
tional Institutes of Health Stroke Scale (NIHSS; range, 0 to 42, with higher scores indicating more severe neurologic 
impairment; scores of ≤6 indicate mild impairment, and scores of ≥25 indicate very severe impairment). Age and 
NIHSS score were used as continuous variables. The variables chosen for multivariate and subgroup analyses were 
prespecified. The cutoff points for age, NIHSS score, and blood pressure were determined with the use of the 
Youden method, after a receiver­operating­characteristic analysis tabulating sensitivity, specificity, and accuracy for 
each possible cutoff point. For time to treatment, patients who did not receive the assigned treatment were exclud­
ed, and an additional patient in the endovascular­treatment group was excluded because the procedure was inter­
rupted owing to equipment breakdown. For stroke cause and territory, the 2 patients with conditions mimicking 
stroke were excluded. For stroke territory, a third patient was excluded because the stroke was in both the posterior 
and anterior circulation. The analysis of major protocol deviations, and all the other subgroup analyses, included the 
12 patients at the center that was withdrawn from the study.
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We did not detect any heterogeneity among 
centers, particularly between high-volume and low-
volume centers — an important distinction, be-
cause a sufficiently large volume of neurointer-
ventional procedures should ensure adequate 
operator experience.25 Operators at all centers 
had the opportunity to participate in training 
meetings organized during the study, in which 
cases or controversial issues could be discussed.
Some issues may affect the generalizability of 
our findings. As in large trials of intravenous 
t-PA,1 the demonstration of vessel occlusion was 
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not a precondition for inclusion in our trial. 
There are several alternative approaches, some of 
which are already used in clinical practice, to 
select patients for endovascular treatment. For 
example, patients can be selected on the basis of 
the demonstration of vascular occlusion with 
noninvasive methods, such as computed tomo-
graphic angiography or magnetic resonance an-
giography. The use of these methods has pros 
and cons. Digital-subtraction angiography offers 
the possibility of treating patients right away, 
without any further loss of time, with the advan-
tage of providing information on the dynamics 
of brain circulation and accurate information on 
the occluded vessel or vessels. We are not able to 
exclude the possibility that endovascular treat-
ment is superior to standard intravenous t-PA in 
patients selected on the basis of the findings of 
computed tomographic angiography or magnet-
ic resonance angiography.
Device technology is advancing rapidly, and it 
is conceivable that the latest-generation devices, 
called stentrievers,13,14 which were used infre-
quently in this trial, could provide greater benefit 
if used widely. This pragmatic trial assessed the 
technology available in the 4 years during which 
it took place. To avoid treatment delay, bridging 
is proposed with the start of intravenous throm-
bolysis while endovascular treatment is being 
organized.26 Our trial hypothesis was that the dis-
advantage of the endovascular treatment in terms 
of time spent, as compared with that required by 
intravenous t-PA, might be offset by more rapid 
and effective revascularization achieved with the 
endovascular approach.
Physicians’ belief that interventional approach-
es were superior to medical treatment was a seri-
ous obstacle in organizing randomized trials in 
the past decade.27 The high rate of recanalization 
with endovascular treatment might give the im-
pression that this method is effective in most 
cases, although it may provide no clinical benefit 
in almost half the patients.28 This trial did not 
show that endovascular therapy achieves superior 
outcomes as compared with intravenous throm-
bolysis, and our findings do not provide support 
for the use of the more invasive and expensive 
endovascular therapy over intravenous treatment.
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